

CELL BIOTECH

Probiotics & Microbiome company



2025 2Q Earnings Release

2025. 08.

As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to the external audit process, and may cause the actual results to differ from those stated or implied in this material.

2q Earnings Summary

Revenue down 5.2% to KRW 11.9 billion, operating profit down 49% to KRW 1.3 billion

Domestic revenue up 3.5%, overseas revenue down 12.6%


Duolac brand sales up 14.8% to KRW 6.9 billion, OEM/ODM sales down 33.3% to KRW 3.2 billion, Raw material sales up 2.5% to KRW 1.8 billion

(unit : KRW 100 mil)


	2024 2q	% of revenue	2025 2q	% of revenue	YoY(%)
Revenue	125.6		119.1		-5.2
Domestic	57.9	46.1	59.9	50.3	3.5
Overseas	67.7	53.9	59.2	49.7	-12.6
	2024 2q	Profit margin (%)	2025 2q	Profit margin (%)	YoY(%)
Operating Profit	25.1	20.0	12.8	10.7	-49.0
Net Profit	40.4	32.2	2.1	1.8	-94.8

2q revenue KRW 11.9 billion, yoy -5.2%, qoq +6.1%

Quarterly revenue



Full year revenue




Profit trends


2q operating profit KRW 1.3 billion, yoy -48.9%

Net Profit KRW +0.2 bil.

Quarterly profit




Full year profit



Revenue breakdown

2q revenue of Duolac brand +14.8% to 6.9 KRW bil., OEM/ODM -33.3% to 3.2 KRW bil., and raw material +2.5% to 1.8 KRW bil.



Microbiome R&D

- 1) Microbiome First-in-Class anticancer pipeline 'PP-P8' clinical phase 1 IND submitted (Mar 5, 2021)
- 2) Acquisition European patent of PP-P8 (Apr 1, 2021) (patent number EP3453718)
- 3) Acquired US patent for Probiotics drug delivery system (22. 12. 20)
- 4) P8 anticancer mechanism paper MOA (23.06.07) Anti-Cancer Roles of Probiotic-Derived P8 Protein in Colorectal Cancer Cell Line DLD-1, Int. J. Mol. Sci, 2023
- 5) Cellbiotech, Colorectal Cancer Drug Phase 1 Clinical Trial Plan Approved by Korea MFDS (Mar 20, 2024)
- 6) Cellbiotech starts phase 1 of microbiome colorectal cancer drug 'PP-P8'

<https://www.hankyung.com/article/202502194939i>

No. 1 in global export for 12 consecutive years

- 1) Cellbiotech's probiotics 'DUOLAC' ranked No. 1 in the world for 12 consecutive years



<https://www.mk.co.kr/en/it/11341049>

FDA GRAS World's Most Listed

1) Cellbiotech "11 types of lactic acid bacteria secured FDA GRAS certification... The World's Largest Holdings"



<https://www.hankyung.com/article/202402222016i>

2) Cellbiotech, Probiotics Leading... Global Leap



<https://www.dailypharm.com/Users/News/NewsView.html?ID=309331&REFERER=NP>

Consolidated Financial Summary

CELL BIOTECH

Income statement

(unit : KRW 100 mil., %)

	2024 2q		2025 2q	
	Amount	Ratio	Amount	Ratio
Revenue	125.6	100	119.1	100
Gross profit	92.0	73.2	88.9	74.6
SG&A expenses	66.9	53.3	76.1	63.9
Operating profit	25.1	20.0	12.8	10.7
Consolidated net income	40.4	32.2	2.1	1.8

Statement of financial position

(unit : KRW 100 mil., %)

	2024 .12	2025 .2Q
Assets	1,304	1,296
Current Assets	972	973
Non current Assets	332	322
Liabilities	62	61
Current Liabilities	59	59
Non current Liabilities	3	1
Shareholder's Equity	1,242	1,296